Introduction
The erbB family of receptor tyrosine kinases consist of four membrane bound receptors: erbB1 (EGFR), erb-B-2 (HER2 or c-neu), erb-B-3 (HER3) and erb-B-4 (HER4). Upon binding of specific ligands, these receptors homo-and hetero-dimerize, become phosphorylated, and activate signaling networks which impact cell differentiation, proliferation, and tumorigenesis (Cohen et al., 1998; Hung and Lau, 1999) . The association between erb-B-2 overexpression and breast tumorigenesis is well documented in humans. Many laboratories, including our own, have studied the relationship between erb-B-2 overexpression and mammary tumor formation using MMTV/c-neu (erb-B-2) transgenic mouse models. In our previous study (Zhou et al., 2001) we made two interesting observations regarding mammary tumorigenesis in MMTVerb-B-2 mice. First, tumor development was associated with conversion of the MMTV promoter from a hypermethylated state, in which the erb-B-2 transgene was not expressed, to a hypomethylated state in which instance the erb-B-2 transgene was expressed, indicating that MMTV promoter de-methylation was a key factor in tumor initiation. Second, we found that mammary tumorigenesis required not only erb-B-2 expression from the transgene, but also endogenous erb-B-3 overexpression (Zhou et al., 2001) . This suggested that tumor formation relied on erb-B-2-erb-B-3 heterodimerization for transmitting proliferative signals to the nucleus.
Erb-B-3 has been less studied as a human oncogene. Overexpression of erb-B-3 is associated with poor prognosis in non-small cell lung cancer (Yi et al., 1997) . It is likely that erb-B-3 overexpression in human tumors requires concomitant overexpression of erb-B-2 or another partner in the erbB pathway. Erb-B-2-erb-B-3 heterodimerization is the most common pair observed in the erbB family. Erb-B-3 differs from other erbB family members in that it has no associated kinase activity . Neureglin [NRG-1] is the ligand for erb-B-3. Receptor occupancy increases the affinity of erb-B-3 for erb-B-2, leading to heterodimerization and kinase activitation of down stream signaling pathways in bronchial epithelium (Polosa et al., 2000) , the developing human fetal lung (Patel et al., 2000) Schwann cells and muscle cells (Jo et al., 1995) , among others. Not only is the erb-B-2-erb-B-3 heterodimer noted in normal cells and tissues but it also is seen in transgenic erb-B-2 targeted to skin (Kiguchi et al., 2000) , NRG-1 overexpressing transgenic mice (Weinstein and Leder, 2000) and in lung cancer cell lines (Sundaresan et al., 1998) .
Previous transgenic mouse models of the erbB family have focused on erb-B-2 overexpression. Since receptor dimerization is essential for stimulation of the intrinsic proliferative pathways and since the most common erb-B-2 partner is erb-B-3, we established MMTV/human-erb-B-3 transgenic mice. We then bred these mice to MMTV/erb-B-2 transgenic mice to generate erb-B-2/erb-B-3 bitransgenic mice to investigate the tumorigenic potential overexpression of both receptors. Furthermore, since lung carcinogenesis is a multistep process, often involving exposure to tobacco carcinogens, we also examined the impact of carcinogen exposure on tumor incidence and latency. We chose the methylating agent, MNU, which mimics the known tobacco carcinogen, NNK (4-(N-methyl-Nnitrosamino)-1-(3-pyridyl)-1-butanone). Both form mutagenic O6-methylguanine DNA adducts which leads to G to A point mutations during DNA replication. Previous studies have shown that both NNK and MNU induce murine lung tumors and that these tumors have a G to A K-ras mutation in codon 12 (Liu et al., 1999) . This is also the site of K-ras mutations in human lung tumors (Peterson et al., 2001; Devereux et al., 1991) . Our studies show that lung tumorigenesis was associated with transgenic erb-B-3 and endogeneous erb-B-2 overexpression and potentiated by MNU-induced K-ras mutational activation. These studies provide the first direct evidence that erb-B-3 overexpression will lead to lung tumorigenesis and that this requires heterodimerization with erb-B-2.
Results
Generation of human erb-B-3 transgenic mice and expression of the transgene Four founders were generated by microinjection of MMTV-h-erb-B-3-bGH poly A transgene DNA into fertilized one-cell mouse zygotes. Insertional integrity of the transgene was determined by Southern blot using genomic DNA isolated from the offspring of founders and digested with SacI or HindIII and EcoRI (Figure 1a) . No band was detected in FVB background mouse DNA whereas a strong signal was seen in offspring of founders 2, 3 and 8, yielding a 3.81 kb fragment, identical in size to the plasmid control, pClaN-ME3b, (Figure 1b ). The expression of human erb-B-3 was detected by RT -PCR in the lung, mammary gland, brain and intestine (Figure 1c) , as well as thymus, liver, and spleen (not shown) in the transgenic offspring of each founder.
Lung tumor development
The most common tumor site in the MMTV/human erbB3 transgenic mice was the lung (Table 1) . Of 26 nontransgenic FVB mice, two developed tumors (7.7%) that were small, 1 -4 mm in size, yielding a total of five tumors were found in the two mice. In contrast, among 40 human erb-B-3 transgenic FVB mice, 11 developed spontaneous lung tumors (27.5%) (P=0.06 compared to non transgenic mice) that ranged in size from 1 to 17 mm, and a total of 29 tumors were seen in the 11 mice (P=0.05 compared to non transgenic mice). A similar incidence of lung tumors was seen in erb-B-2/erb-B-3 bitransgenic mice, seven out of 23 mice had lung tumors (30.4%) (P=0.06 compared to nontransgenic mice), with a total of 33 lung tumors were identified (P=0.01 compared to nontransgenic mice).
We also studied whether the methylating carcinogen, MNU, would impact lung tumor development in the transgenic mice. In the FVB background nontransgenic mice treated with MNU, four out of 25 mice developed a total of 20 lung tumors (16%) all of which were small, 1 -4 mm. In contrast, h-erb-B-3 transgenic mice treated at 5 weeks of age with MNU had an incidence of lung tumors of 57.1% (12 out of 21 mice) (P=0.01 compared to treated FVB mice) that were larger, 1 -21 mm, including 10 tumors larger than 5 mm compared to none of the MNU induced tumors seen in the FVB wild type mice. A total of 63 tumors were seen after MNU in h-erb-B-3 transgenic mice (P=0.01 compared to non transgenic mice). In r-erb-B-2/h-erb-B-3 bitransgenic mice treated with MNU, the incidence of lung tumors was similar to that of the h-erb-B-3 transgenic mice, 45.5% (five out of 11 mice). Overall, the incidence of lung tumors in the h-erb-B-3 and r-erb-B-2/h-erb-B-3 transgenic mice compared to FVB mice was 18 out of 63 (29%) in untreated mice and 17 out of 32 MNU treated mice (53%), (P50.01 compared to FVB mice).
The latency of lung tumor development is shown in Figure 2 using a Kaplan -Meier plot. In this plot, mice sacrificed because of another tumor and those sacrificed without tumors were censored. Compared with spontaneous lung tumor development in h-erb-B-3 transgenic mice, the latency was much shorter in h-erb-B-3 mice treated with MNU (718 days in untreated mice vs 430 days in treated mice, P50.001). While the incidence of tumors was higher in the h-erb-B-3 transgenic mice than nontransgenics, the latency was similar. On the other hand, while the incidence of lung tumors was similar in bitransgenic r-erb-B-2/h-erb-B-3 and h-erb-B-3 mice, the latency was shorter in the bitransgenic mice and shorter still after MNU treatment (459 in untreated r-erb-B-2/h-erb-B-3 mice vs 268 days in treated r-erb-B-2/h-erb-B-3 mice, P50.001) (Table 1 and Figure 2a,b) .
Other tumors in h-erb-B-3 transgenic mice
Other tumors in these mice were consistent with the tumors seen after MNU in normal mice -lymphomas predominated, and in r-erb-B-2 transgenic mice, mammary tumors were seen ( Table 2 ). The expression of human erb-B-3 did not alter the incidence of these tumors, even after MNU. Notably, mammary tumors were not increased in h-erb-B-3 mice even though the herb-B-3 transgene was expressed in the mammary gland. In MNU-treated mice, only 1 h-erb-B-3 transgenic mouse developed a mammary tumor, whereas four out of 11 r-erb-B-2/h-erb-B-3 bitransgenic mice developed mammary tumors with a latency of 250 days (similar to that of the ebrB-2 transgenic mice (Zhou et al., 2001) ). MNU induced thymic lymphomas occurred with the cumulative incidence of 44% in wild-type FVB mice with a mean latency of 180 days. A similar incidence (47.6% and 45.5%) of MNU-induced lymphomas was observed in h-erb-B-3 transgenic and r-erb-B-2/h-erb-B-3 bitransgenic mice with a mean latency of 194 days in r-erb-B-2 and 184 days in r-erb-B-2/h-erb-B-3 mice (Table 2 ). Other tumors occurred rarely, including ovarian tumors, uterine tumors and sarcomas.
Histopathology of lung tumors In h-erb-B-3 transgenic mice
Most of the lung tumors were adenocarcinomas (Table  3 and Figure 3 ). Many were poorly differentiated, and others were papillary adenocarcinomas. Many h-erb-B-3 transgenic mice contained multiple tumors of both phenotypes in a multicentric fashion. Some tumors clearly invaded the lung from an endobronchial. No distant metastases were seen. MNU did not affect the distribution of tumor type, degree of invasion or multicentricity.
Expression of human erb-B-3 transgene and endogenous erb-B-2 in lung tumors
We analysed the expression of erbB family proteins in lung tumors by Western blotting and immmunohistochemistry. As depicted in Figure 4 , both transgenic herb-B-3 and endogenous erb-B-2 were highly expressed in all MNU-induced and spontaneous lung tumors of h-erb-B-3 transgenic mice. Expression of the h-erb-B-3 transgene and endogenous serb-2 was much lower in the normal lung of transgenic mice and the endogenous erb-B-2 was also expressed sat low levels in the lung of nontransgenic mice. Expression of endogenous erbB family proteins could not be analysed in the tumors of the FVB nontransgenic mice because the tumors were too small and the amount of tissue was insufficient. Erb-B-4 was detected at lower levels than either erb-B-2 or erb-B-3 in many of the transgenic lung tumors but not in normal lung. No EGFR was detected in normal or tumor tissue. Anti-phosphotyrosine blot of the Western blot indicated that only erb-B-2 and erb-B-3 (but not erb-B-4) were phosphorylated (data not shown). Immunostaining of erb-B-2 and erb-B-3 also showed high expression in all of the erb-B-3 transgenic lung tumors (Figure 3e ,f), including those induced by MNU, indicating that the erbB pathway was critical to tumorigenesis, even with MNU, in which case K-ras mutations were also observed (see below). Of note, endogenous erb-B-4 was expressed at low levels in spontaneous tumors and to a much higher extent in MNU-induced lung tumors of h-erb-B-3 transgenic mice, indicating that some degree of cross induction of the erbB family occurred following MNU exposure, again, perhaps due to K-ras activation.
Evaluation of the downstream targets of the erbB pathway for activation in lung tumors
Erb-B-2/erb-B-3 heterodimerization and phosphorylation leads to a series of downstream signal transduction phosphorylation reactions, of which SHC and MAPK are well recognized as essential. As shown in Figure 4 , SHC, a 66 kd protein was present in the lung tumors but not in normal lung tissues. MAPK phosphorylation was investigated using a phosphorylation-specific anti-p42/44 MAPK antibody. As depicted in Figure 4 , MAPK was not phosphorylated in h-erb-B-3 transgenic and FVB background mouse normal lung, but was phosphorylated in both MNU-induced and, to a lesser extent, spontaneous h-erb-B-3 transgenic lung tumors. As noted above, the lung tumors in FVB mice were too small to analyse by Western blot and immunohistochemistry was not informative in the small samples available.
K-ras mutations in lung tumors
K-ras mutations are common in mouse tumors after MNU treatment because of mutational activation of codon 12 [GGT to GAT] results from O 6 -methylguanine DNA adducts at the second G. This mutational Twenty lung tumor samples (13 from MNU treated mice and seven from untreated mice) from erb-B-3 transgenic or erb-B-2/erb-B-3 bitransgenic mice were evaluated for K-ras mutations using an PCR -RFLP method we have previously described (Zaidi et al., 1995) . In the 13 tumors from MNU treated mice, nine had evidence of G to A point mutations in codon 12 of K-ras consistent with an activating mutation. None of the lung tumors from untreated mice (0/7) had a K-ras mutation on codon 12 (Table 1) .
Discussion
In this study, we generated the first human erb-B-3 transgenic mice and demonstrated that these mice were susceptible to lung tumorigenesis. Furthermore, when the human erb-B-3 and rat erb-B-2 transgenic mice were bred to generate bitransgenic mice, the lung tumor latency was shortened significantly. The environmental methylating agent, MNU -a methylating agent related to NNK, the known tobacco carcinogen -potentiated the lung carcinogenicity by significantly shortening tumor latency, and increasing tumor incidence. This was in part due to activating Kras mutations. Erb-B-3 overexpression has been documented in lung cancer cell lines (al Moustafa et al., 1999) and in nonsmall cell lung cancer (Yi et al., 1997; Reinmuth et al., 2000) . When it is present, erb-B-3 heterodimerizes with erb-B-2 resulting in autophosphorylation of both receptors and initiation of the ras/MAPK proliferative cascade. Erb-B-3 overexpression is associated with more advanced non-small cell lung cancer and a poor prognosis (Yi et al., 1997) and is more commonly observed in squamous cell than adeno or large cell carcinomas. In human non-small cell lung cancer, the frequency of erb-B-3 overexpression -29% - (Yi et al., 1997 ) is similar to the frequency of erb-B-2 overexpression, 37%, (Kristiansen et al., 2001) suggesting that both cooperate in lung carcinogenesis.
K-ras mutations are common in human lung cancers (Ahrendt et al., 2001) , and appear induced by tobacco carcinogens including the methylating agent, NNK. In mouse models, both NNK and the related compound, MNU induce lung tumors (Liu et al., 1999) . Our model shows an interaction between erbB3 overexpression and methylating agent-induced K-ras activation both in shortening the tumor latency and increasing cell proliferation pathway phosphorylation. As such, it may provide an important link between methylating agent carcinogenesis and the erbB pathway. Methylating agents form O 6 -methylguanine DNA adducts causing G to A activating transition mutations in codon 12-GGT-of K-ras (Zaidi et al., 1995) . This carcinogenic process occurred in our studies, with MNU treatment resulting in K-ras mutations in lung tumors arising in erb-B-3 transgenic mice. As a result, MNU caused enhanced lung tumorogenicity and shortened latency. Since K-ras mutations occurring in human lung cancer are also presumed to be associated with carcinogen exposure, the mouse model appears to mimic the pathogenesis of human tumors.
We have found in other mouse MNU carcinogenesis studies (Dumenco et al., 1993; Qin et al., 1999a,b; Reese et al., 2001; Zhou et al., 2001 ) that predisposing oncogenic processes such as mismatch repair defects (Qin et al., 1999a,b) , erb-B-2 over-expression (Zhou et al., 2001) , or p53 mutation (Reese et al., 2001 ) increase the carcinogenicity of MNU. In these other studies, the thymus, mammary gland and colon, have been the tissue targets. In contrast, in the current study even though h-erb-B-3 was over-expressed in the mammary gland and the thymus, MNU did not induce a higher incidence of tumors at either site. This suggests that there is tissue specificity in the tumor induction process that is more complex than simply the permissive genetic background of erb-B-3 overexpression. One obvious possibility is that endogenous erb-B-2 was not induced in these organs so that the erbB pathway was not activated in the mammary gland or the thymus. While possible, it is unlikely that the erb-B-3 transgene insertion site resulted in altered gene expression predisposing to lung carcinogenesis, since offspring of Figure 4 K-ras mutation and Western blot of erbB family and MAPK pathway proteins in lung tissues. The status of K-ras mutation is indicated as (+) with, or (7) without K-ras mutation. In erb-B-3 transgenic mouse normal lung tissue and in FVB nontransgenic mice, Western blots show erb-B-2, erb-B-3 and erb-B-4 were not overexpressed, and MAPK and SHC were not activated. In erb-B-3 transgenic mice with spontaneous (B3-123, B3-345, B3-346), and MNU-induced lung tumors (B3-194, B3-205, B3-244) and in a spontaneous erb-B-2/erb-B-3 bigenic mouse lung tumor (NB45), erb-B-2, erb-B-3 and erb-B-4 were overexpressed; and MAPK and SHC were phosphorylated. Loading control blotted with B-actin was shown on the bottom panel. Each membrane was reacted with antibodies to either both erb-B-2 and phospho-p44/42 MAPK; erb-B-3 and total MAPK; erbB4 and SHC; or erbB1 (no detectable signal) and B-actin three different founders used in these studies were lung cancer prone.
Tumor histology showed a spectrum of tumors, all expressing h-erb-B-3 and endogenous erb-B-2. All of the tumors in nontransgenic mice were small, 1 -4 mm. In the transgenic mice, we observed larger, multicentric tumors with a variety of histologic types, the majority of which were papillary and epithelial adenocarcinomas although sarcomas, and neurocrine origin-like tumors were also seen. Since erb-B-2 and erb-B-3 overexpression are seen in human epithelial and adenomatous lung carcinomas (Yi et al., 1997) , (Kristiansen et al., 2001) , the murine lung tumors reported here appear similar in oncogenic etiology to the clinically observed tumors, particularly those associated with K-ras mutation and tobacco smoke (Ahrendt et al., 2001) . While overexpression of Erb-B-3 is a poor prognostic finding in humans (Yi et al., 1997) , the lung tumors in erb-B-3 transgenic mice did not appear to metastasize beyond the lung, although most were multicentric.
Co-expression of erb-B-2 and erb-B-3 may play a critical role in lung tumor formation. For instance, in human carcinomas of mammary, ovary, prostate and colon, high expression of erb-B-2 and erb-B-3 has been documented (Adamson and Wiley, 1997) although interactions between erb-B-2 and erb-B-3 in human tumors may be hard to detect in vivo (Muller et al., 1996) . While erb-B-3 does not have intrinsic protein tyrosine kinase activity, and must heterodimerize with another kinase active signalling protein such as an erbB receptor (erb-B-1,2,or 4) (Plowman et al., 1990; , it can undergo tyrosine phosphorylation, expanding the repertoire of intracellular signaling proteins recruited into the erbB response pathway ; (Schlessinger, 2000) . We noted that all of the lung tumors of h-erb-B-3 transgenic mice also over-expressed endogenous erb-B-2, supporting the need for heterodimerization. Of interest, when we crossed the erb-B-2 with erb-B-3 mice, the result was a similar incidence of tumors but a much shorter latency. This suggests synergy between erb-B-2 and erb-B-3 in tumor progression (not initiation), yielding larger tumors more rapidly than in erb-B-3 transgenic mice. The mechanism of increased expression of endogenous erb-B-2 as a result of transgene overexpression of erb-B-3 is unclear. It most likely involves selection of cells over-expressing both erbB family proteins leading to a proliferative signal and a growth advantage. Of interest, while erb-B-4 expression could be detected in the tumors, we were not able to identify phosphorylation of erb-B-4, so its function in the pathway of these tumors remains unclear.
The signaling cascade that is activated in these mice is consistent with erbB and K-ras activation. Thus, SHC and MAPK were over-expressed and phosphorylated in the tumors but not in the normal tissue of the transgenic mice. K-ras activation by MNU appears to have both an initiating effect, resulting in higher incidence, and a progression effect, resulting in shorter latency. Therefore, in this murine model of lung carcinogenesis, heterodimerization between transgenic erb-B-3 and endogenous erb-B-2 appears to be essential, while MNU induced K-ras mutation and activation, appears to synergize with but did not replace the erbB pathway in both tumor induction and progression.
In summary, this is the first mouse model demonstrating an association between erb-B-3 overexpression and lung carcinogenesis. It appears similar to human lung carcinogenesis based on histology, erb-B-2 overexpression, sensitivity to methylation mutagenesis and K-ras activation, mimicking tobacco as the carcinogen. This model may serve as an excellent model with which to evaluate other carcinogenic agents, other oncogenic signaling pathways, the importance of genetic background and modifier genes in tumor incidence, and the potential value of chemopreventive agents in this malignancy.
Materials and methods

Antibodies
Primary antibodies against Erb-B-1/EGFR, c-Erb-B-2 and Erb-B-3 were purchased from NeoMarker (Union City, CA, USA); anti-Erb-B-4 from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-SHC, anti-MAP kinase R2 from Upstate Biotechnology (Lake Placid, NY, USA); antiphospho-P44/42 MAP Kinase from Cell Signaling Technology (Beverly, MA, USA); and actin from Sigma. HRPconjugated anti-rabbit antibody was purchased from Amersham (Piscataway, NJ, USA). Rabbit anti-mouse IgG was obtained from Upstate Biotechnology (Lake Placid, NY, USA).
Transgenic mice
MMTV promoted human erbB3 (pCla12N-ME3b) was constructed by Dr Adam W Grasso. Plasmid pBS-erbB3 bearing human erbB3 cDNA was cut with SalI/KpnI, treated with Klenow and recut with SalI. pCla12N-MMb containing the MMTV promoter, the MGMT gene, the bovine growth hormone [bGH] exon 5 and the poly A region, was cut with BamHI, treated with Klenow and recut with SalI. After gel purification, the fragment containing erb-B-3 was ligated into the plasmid containing the MMTV promotor in a SalI/blunt reaction. This generated a MMTV-h-erb-B-3-bGH poly A transgene in the plasmid pClaN-ME3b. Erb-B-3 transgenic mice were generated by blastocyst injection of the HindIIIEcoRI fragment (Figure 1) by Edison Biotechnology Institute, Ohio University, Athens, Ohio, using FVB background mice. Four strains of erbB3 founder transgenic mice were bred with the FVB background mice to generate F1 heterozygote erb-B-3 transgenic mice. For genotype testing, 0.3 cm tail clips were digested in 300 ml proteinase K solution: (50 mM Tris HCl (pH 7.5), 10 mM EDTA, 100 mM NaCl, 1% Triton and 1 mg/ml proteinase K) over night at 558C. Mice carrying the human erb-B-3 transgene were identified by PCR amplification of tail DNA. The human erb-B-3 primers were: forward 5'-CCA TCT TCG TCA TGT TGA ACT ATA ACA C-3', reverse: 5'-TAC ACA AAC TCC TCC ATA CTG ATA CTT-3'. This primer set yields a 515 bp fragment. For bitransgenic mice, the rat erb-B-2 primer sequences used have been previously published (Siegel et al., 1994) . PCR was performed under the following conditions: 10 mM Tris-HCl pH 8.3, 1.5 mM MgCl 2 , 50 mM KCl, 50 mM dNTPs, 500 nM of each primer, 5 ml 10 times diluted tail DNA, 0.5 U TaqDNA polymerase for total volume of 25 ml. Thirty cycles of PCR were utilized: 948C for 30 s, 588C for 30 s, 728C for 30 s.
Animal treatment
Twenty-one h-erb-B-3 transgenic mice, 11 r-erb-B-2/h-erb-B-3 bigenic mice and 25 non-transgenic mice were given a single i.p. injection of MNU (Sigma, St. Louis, MO, USA) at a dose of 50 mg/kg body weight at 5 weeks of age. Forty h-erb-B-3 transgenic mice, 18 r-erb-B-2/h-erb-B-3 bitransgenic mice and 26 non-transgenic were observed for spontaneous tumor development. The mice were carefully observed three times a week and sacrificed at the time when they were noticed to have protruding mammary gland, dyspnea or abdominal distention. The sacrifice date was recorded as the time of onset. The mice were sacrificed under carbon dioxide (CO 2 ) anesthesia and autopsied. For those lung tumors bigger than 5 mm, half was saved for RNA and DNA preparation. For tumors bigger than 8 mm, a portion was saved for protein preparation. The tumor and organ sections were further divided and frozen in liquid nitrogen and stored at -808C or fixed in 10% buffered formalin and embedded in paraffin for H&E or immunostaining. Lung tumor-free survival curves were plotted by Kaplan -Meier Cumulative Survival Curves and compared by standard statistical techniques using Statview software with the Chi-square test. Mean tumor latencies were compared by t-test.
Southern blot
Genomic DNA from thymus, heart, liver or brain was purified with DNAzol. Thirty micrograms genomic DNA were digested with SacI or HindIII and EcoRI. DNA was transferred to nylon membrane, and then hybridized with human erb-B-3 PCR product isolated from transgenic mouse tail DNA.
RT -PCR
Total RNA was extracted from 25 mg of both tumor and normal lung tissues using Trizol Reagent (GibcoBRL) and treated with DNase I (Boehringer Mannheim, Indianapolis, IN, USA). Approximately 10 mg RNA was treated with 2 units RNase-free DNase I in 20 mM Tris-Cl (pH 8.0) 10 mM MgCl 2 for 20 min at 378C. Reverse transcription was performed under the following conditions: 0.5 mg oligo (dT)12 -18 , 2 mg RNA, 20 mM Tris HCl, 50 mM KCl, 2.5 mM MgCl 2 , 0.5 mM dNTPmix, 10 mM DTT, 200 U SuperScript II RT, total volume of 20 ml for 1 h at 428C. Two microliters aliquots were used in PCR reactions following the same conditions as above. A commercial PCR set for 18 s rRNA (Ambion, Inc, Austin, TX, USA) was used as a standard for the reaction.
Western blotting
Tumor and normal lung tissues were sonicated in ice-cold RIPA buffer containing protease and tyrosine phosphatase inhibitors (50 mM Tris-Cl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 1 mM PMSF, 1 mg/ml pepstatin A, 0.2 U/ml aprotinin, 0.5 mg/ml leupeptin, 1 mM Na 3 VO 4 ) and cleared by centrifugation at 14000 r.p.m. for 2 min. Fifty micrograms of total tissue proteins were boiled for 5 min, loaded on 4 -15% gradient gel and subjected to electrophoresis. Proteins were then transferred to PVDF membranes (Biotechnology Systems, Boston, MA, USA). After blocking in 5% non-fat dry milk-TBST (10 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20) for 1 h at RT, blots were incubated with primary antibody overnight at 48C, washed 36 with TBST, incubated with HRP-conjugated secondary antibody for 1 h, washed 36 with TBST, then developed by ECL (Amersham) and exposed to X-Omat film (Kodak, NEN Life Science).
Histology and immunohistochemistry
Three-micron sections were placed on regular slides and stained with hematoxylin and eosin. Four-micron sections were applied to lycine coated slides. After deparaffinization and rehydration, antigen unmasking was performed by heat treatment in 10 mM sodium citrate buffer (pH 6.0) at 958C for 5 min. Slides were allowed to cool in the buffer for 20 min and washed with deionized H 2 O. Endogenous peroxidase activity was quenched by 5 min incubation in 0.5% hydrogen peroxide. After blocking for 30 min in 0.5% goat serum in 16 PBS, the sections were incubated overnight at 48C with a primary goat polyclonal antibody against erb-B-2 or erb-B-3 (Santa Cruz Biotechnology, Inc.) at a dilution of 1 : 100. Primary antibody binding was localized by using an avidin-biotin-peroxidase kit, ImmunoCruz Staining Systems (Santa Cruz Biotechnology, Inc.).
PCR-RFLP for mutation screen of K-ras
Thirteen MNU-induced and seven spontaneous lung tumors were checked for activating G to A transition mutations in codon 12 of K-ras using a two-step PCR -RFLP method, as previously described (Qin et al., 1999a) , (Zaidi et al., 1995) .
